[Prevention of aspirin-induced angioedema with an association of leukotriene inhibitors and antihistamines].
Eymard
B
B
Unité d'Immunologie Clinique et Allergologie, Service de Pneumologie, Centre Hospitalier Lyon Sud, 69495 Pierre-Bénite.
Cousin
F
F
Nicolas
J-F
JF
D000085:Acetates / Q000008:administration & dosage*; D000799:Angioedema / Q000139:chemically induced* / Q000517:prevention & control*; D001241:Aspirin / Q000009:adverse effects*; D017332:Cetirizine / Q000008:administration & dosage*; D003521:Cyclopropanes; D003875:Drug Eruptions / Q000209:etiology* / Q000517:prevention & control*; D004359:Drug Therapy, Combination; D005260:Female; D039563:Histamine H1 Antagonists, Non-Sedating / Q000008:administration & dosage*; D006801:Humans; D020024:Leukotriene Antagonists / Q000008:administration & dosage*; D008875:Middle Aged; D011804:Quinolines / Q000008:administration & dosage*; D013440:Sulfides
D000085:Acetates; D003521:Cyclopropanes; D039563:Histamine H1 Antagonists, Non-Sedating; D020024:Leukotriene Antagonists; D011804:Quinolines; D013440:Sulfides; C093875:montelukast; D001241:Aspirin; D017332:Cetirizine